Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Multistate Illegal Marketing Settlement

GlaxoSmithKline agreed to pay a total of $105 million to 44 states and the District of Columbia to settle allegations that the company unlawfully promoted its asthma drug, Advair, and antidepressant drugs Paxil and Wellbutrin. Glaxo was accused by the states of illegally marketing Advair for use by mild asthma sufferers, and Paxil and Wellbutrin for use by children and teenagers without approval by the Food and Drug Administration (FDA). Under the agreement, Glaxo, which did not admit any liability or wrongdoing, agreed to cease paying health care providers to promote its products and giving sales representatives incentives to promote its drugs for unapproved uses. The agreement also bans Glaxo from disseminating information describing any off-label use of a product, unless such information and materials are consistent with applicable FDA regulations and guidance.

Misconduct Type
Health
Enforcement Agency
State/Local
Contracting Party
None
Court Type
Civil
Disposition
Settlement
Date of Settlement Announcement
6/4/2014
Contractors Involved Penalty
Total
GlaxoSmithKline $105,000,000
Further Information Released
California AG Press Release 6/4/2014
Complaint (California) 6/4/2014
Final Judgment (California) 6/4/2014

Federal Contractor Misconduct Database